A Randomized, Double Blind Placebo Controlled Study Of Efficacy And Tolerability Of Withaina Somnifera Extracts In Knee Joint Pain
Notes for this study:
||mWOMAC. Placebo: before 50.45 ± 2.11, after 48.24 ± 2.31. 250 mg ashwagandha: before 51.15 ± 2.39, after 44.6 ± 1.4. 500 mg ashwagandha: before 53.1 ± 2.90, after 37.65 ± 2.41
|Number of Subjects
||30-44, 45-64, 65+
In a randomized, double-blind, placebo-controlled trial, 60 participants with knee joint pain were assigned to take ashwagandha at a dose of 250 mg or 500 mg (standardized to not less than 10% Withanolide glycosides, not less than 32% oligosaccharides and not more than 0.5% of Withaferin- A), or placebo daily for 12 weeks.
The primary outcome was the percentage change in the Modified Western Ontario and McMaster University Osteoarthritis Index (mWOMAC) after 12 weeks. There was a statistically significant reduction in score for both groups compared with placebo, and the high dose group saw a greater, statistically significant reduction compared with the low dose group. Knee swelling only declined in the high dose group compared with the placebo, while the groups had the same relationship for pain, stiffness and physical function as for the overall score. The same was the case for pain on a visual analog scale.
The frequency of using rescue medication was 10 participants in the high dose group, 13 in the low dose group, and 17 in the placebo group. No notable adverse events or worrying blood tests were found.